Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum
Akebia Therapeutics (AKBA) will hold investor meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum on October 14, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Akebia Therapeutics (AKBA) will hold investor meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum on October 14, 2026.
CEO John P. Butler, Chief R&D and Medical Officer Dr. Steven Burke, and Chief Financial and Chief Business Officer Erik Ostrowski will participate in one-on-one meetings. Management will discuss the company's commercial products and clinical-stage pipeline assets for rare kidney diseases.
Details
News Market Reaction – AKBA
On Oct 7, the day this news came out, AKBA closed 0.48% below the previous close.
Data tracked by StockTitan Argus for the Oct 7 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, Dr. Steven Burke, Chief R&D and Medical Officer, and Erik Ostrowski, Chief Financial and Chief Business Officer, will participate in one-on-one meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum on October 14, 2026.
During meetings, management will discuss its commercial products and clinical stage, differentiated pipeline assets for rare kidney diseases.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Waltham, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com
